Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
The combination of durvalumab with etoposide and either cisplatin or carboplatin has been studied in the treatment of extensive-stage small-cell lung cancer (ES-SCLC).
The combination of durvalumab with etoposide and either cisplatin or carboplatin has been approved for the first-line treatment of patients with extensive-stage small cell lung cancer based on NCT03043872 - CASPIAN - Durvalumab + Tremelimumab + Carboplatin or Cisplatin + Etoposide -vs. Durvalumab + Carboplatin or Cisplatin + Etoposide vs. Carboplatin or Cisplatin + Etoposide & Small-cell lung cancer and is considered an accepted standard of care option in this setting
see also:
[Chemotherapy (CT) + Immune checkpoint inhibitors (ICIs) & Small-Cell-Lung-Cancer (SCLC)](brain://heSDnxAEDUe1MMqf1im4dg/…